Labetalol does not decrease placental perfusion in the hypertensive term-pregnant rat

Am J Obstet Gynecol. 1989 Feb;160(2):480-4. doi: 10.1016/0002-9378(89)90476-6.

Abstract

The acute effect of labetalol hydrochloride, a combined nonspecific beta-adrenergic and postsynaptic alpha 1-adrenergic blocker, on maternal hemodynamics and organ perfusion was investigated in 10 hypertensive, term-pregnant, spontaneously hypertensive rats with the use of the radioactive-labeled microsphere technique. The normal fall in blood pressure during pregnancy was prevented by the reduction of litter size to two conceptuses on day 7 of gestation. Labetalol (1 to 6 mg/kg) effectively lowered mean arterial pressure 22% by decreasing cardiac output 16%; total peripheral resistance was not significantly decreased. Thus, the blood pressure lowering effect of labetalol was due primarily to its beta-adrenergic blocking effect. Regional flows to the carcass and splanchnic circulation were decreased 19% and 15%, respectively, after labetalol administration. Uterine wall and ovarian perfusion were significantly reduced, but placental perfusion was not significantly altered. Because labetalol lowers blood pressure without reducing placental perfusion, it may be a useful alternative to hydralazine for the treatment of hypertensive emergencies in pregnancy.

MeSH terms

  • Animals
  • Female
  • Genitalia, Female / blood supply
  • Hemodynamics / drug effects
  • Hypertension / physiopathology*
  • Labetalol / pharmacology*
  • Muscles / blood supply
  • Placenta / blood supply*
  • Placenta / drug effects
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / physiopathology*
  • Rats
  • Rats, Inbred SHR
  • Regional Blood Flow / drug effects
  • Splanchnic Circulation / drug effects

Substances

  • Labetalol